Switching to the Dry-Powder Inhaler Easyhaler
Adherence
Asthma
COPD
Compliance
Dry-powder inhaler
Easyhaler
Patient-centered outcomes
Pressurized metered-dose inhaler
Respiratory function
Journal
Pulmonary therapy
ISSN: 2364-1746
Titre abrégé: Pulm Ther
Pays: United States
ID NLM: 101687144
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
19
07
2021
accepted:
07
09
2021
pubmed:
29
9
2021
medline:
29
9
2021
entrez:
28
9
2021
Statut:
ppublish
Résumé
Asthma and chronic obstructive pulmonary disease (COPD) are major causes of morbidity and mortality worldwide. Optimal control of these conditions is a constant challenge for both physicians and patients. Poor inhaler practice is widespread and is a substantial contributing factor to the suboptimal clinical control of both conditions. The practicality, dependability, and acceptability of different inhalers influence the overall effectiveness and success of inhalation therapy. In this paper, experts from various European countries (Finland, Germany, Hungary, Italy, Poland, Spain, and Sweden) address inhaler selection with special focus on the Easyhaler
Identifiants
pubmed: 34581994
doi: 10.1007/s41030-021-00174-5
pii: 10.1007/s41030-021-00174-5
pmc: PMC8477976
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
409-427Informations de copyright
© 2021. The Author(s).
Références
World Health Organization. Chronic obstructive pulmonary disease (COPD). Geneva, Switzerland: WHO, 2015. https://www.who.int/respiratory/copd/en/ [Last accessed Jul 10, 2021].
GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020;8:585–96.
Brakema EA, Tabyshova A, Van Der Kleij RMJJ, et al. The socioeconomic burden of chronic lung disease in low-resource settings across the globe—an observational fresh air study. Respir Res. 2019;20:291.
pubmed: 31864411
pmcid: 6925865
Miravitlles M, Sliwinski P, Rhee CK, et al. Predictive value of control of COPD for risk of exacerbations: an international, prospective study. Respirology. 2020;25:1136–43.
pubmed: 32249487
Price D, Fletcher M, Van Der Molen T. Asthma control and management in 8000 European patients: the recognise asthma and link to symptoms and experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.
pubmed: 24921985
pmcid: 4373302
Sanchis J, Gich I, Pedersen S, Aerosol Drug Management Improvement Team (ADMIT). Systematic review of errors in inhaler use: Has patient technique improved over time? Chest. 2016;150:394–406.
pubmed: 27060726
Kaplan A, van Boven JFM. Switching inhalers: a practical approach to keep on UR RADAR. Pulm Ther. 2020;6:381–92.
pubmed: 33051824
pmcid: 7672131
Mäkelä MJ, Backer V, Hedegaard M, et al. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107:1481–90.
pubmed: 23643487
Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16:249–54.
pubmed: 14572322
Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–8.
pubmed: 21367593
Gregoriano C, Dieterle T, Breitenstein AL, et al. Use and inhalation technique of inhaled medication in patients with asthma and COPD: Data from a randomized controlled trial. Respir Res. 2018;19:237.
pubmed: 30509268
pmcid: 6276152
Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19:10.
pubmed: 29338792
pmcid: 5771074
Lavorini F. Easyhaler
pubmed: 31210773
pmcid: 6555222
Lavorini F, Janson C, Braido F, Stratelis G, Løkke A. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019;13:1753466619884532.
pubmed: 31805823
pmcid: 6900625
Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017;5:1071-81.e9.
pubmed: 28286157
Farkas A, Horváth A, Kerekes A, et al. Effect of delayed pMDI actuation on the lung deposition of a fixed-dose combination aerosol drug. Int J Pharm. 2018;547:480–8.
pubmed: 29886099
Malmström K, Sorva R, Silvasti M. Application and efficacy of the multi-dose powder inhaler, Easyhaler, in children with asthma. Pediatr Allergy Immunol. 1999;10:66–70.
pubmed: 10410920
Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30:381–7.
pubmed: 28933581
pmcid: 5915227
Malmberg P, Rytilä P, Happonen P, Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int J Chron Obstruct Pulmon Dis. 2010;5:257–62.
pubmed: 20714380
pmcid: 2921694
Malmberg LP, Everard ML, Haikarainen J, Lähelmä S. Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler. J Aerosol Med Pulm Drug Deliv. 2014;27:329–40.
pubmed: 24978441
pmcid: 4175975
Azouz W, Chetcuti P, Hosker HS, Saralaya D, Stephenson J, Chrystyn H. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2015;28:35–42.
pubmed: 24815999
Jõgi R, Mattila L, Vahteristo M, et al. Inspiratory flow parameters through dry powder inhalers in healthy volunteers and patients with chronic obstructive pulmonary disease (COPD): device resistance does not limit use in COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:1193–201.
pubmed: 33958863
pmcid: 8096421
Palander A, Mattila T, Karhu M, Muttonen E. In vitro comparison of three salbutamol-containing multidose dry powder inhalers: Buventol Easyhaler
Koskela T, Malmström K, Sairanen U, Peltola S, Keski-Karhu J, Silvasti M. Efficacy of salbutamol via Easyhaler unaffected by low inspiratory flow. Respir Med. 2000;94:1229–33.
pubmed: 11192960
Turpeinen A, Eriksson P, Happonen A, Husman-Piirainen J, Haikarainen J. Consistent dosing through the salmeterol-fluticasone propionate Easyhaler for the management of asthma and chronic obstructive pulmonary disease: robustness analysis across the Easyhaler lifetime. J Aerosol Med Pulm Drug Deliv. 2021;34:189–96.
pubmed: 32960127
pmcid: 8219197
Watts N, Amann M, Arnell N, et al. The 2019 report of The Lancet Countdown on health and climate change: ensuring that the health of a child born today is not defined by a changing climate. Lancet. 2019;394:1836–78.
pubmed: 31733928
National Health Service (NHS) England. Delivering a “net zero” National Health Service. London, UK: NHS England and NHS Improvement, 2020. https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2020/10/delivering-a-net-zero-national-health-service.pdf [Last accessed Jul 10, 2021].
Starup-Hansen J, Dunne H, Sadler J, Jones A, Okorie M. Climate change in healthcare: exploring the potential role of inhaler prescribing. Pharmacol Res Perspect. 2020;8: e00675.
pubmed: 33124196
pmcid: 7596665
Tennison I, Roschnik S, Ashby B, et al. Health care’s response to climate change: a carbon footprint assessment of the NHS in England. Lancet Planet Health. 2021;5:e84–92.
pubmed: 33581070
pmcid: 7887664
Orion Pharma. Carbon life cycle assessment report for Orion corporation: executive summary. 2020. Available from: https://www.orion.fi/globalassets/documents/orion-group/sustainability/2020-orion-pharma-product-footprint-exec-summary.pdf [Last accessed Jan 2021].
Wilkinson AJK, Anderson G. Sustainability in inhaled drug delivery. Pharm Med. 2020;34:191–9.
Wilkinson AJK, Braggins R, Steinbach I, Smith J. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open. 2019;9: e028763.
pubmed: 31662306
pmcid: 6830591
Tamási L, Szilasi M, Gálffy G. Clinical effectiveness of budesonide/formoterol fumarate Easyhaler
pubmed: 30066185
pmcid: 6096955
Gálffy G, Szilasi M, Tamási L. Effectiveness and patient satisfaction with budesonide/formoterol Easyhaler
pubmed: 32026408
pmcid: 6966925
Henning R, Vinge I, Syk J, et al. Prospektive, offene, multizentrische, nicht interventionelle Studie bei erwachsenen Patienten mit Asthma oder COPD zur Erhebung der klinischen Wirksamkeit des Salmeterol/Fluticason Easyhalers in der täglichen Praxis. Deutsche Gesellschaft für Innere Medizin 2021 [German.]
Price D, Thomas V, von Ziegenweidt J, Gould S, Hutton C, King C. Switching patients from other inhaled corticosteroid devices to the Easyhaler(®): historical, matched-cohort study of real-life asthma patients. J Asthma Allergy. 2014;7:31–51.
pubmed: 24748807
pmcid: 3986277
Pirożyński M, Hantulik P, Almgren-Rachtan A, Chudek J. Evaluation of the efficiency of single-inhaler combination therapy with budesonide/formoterol fumarate in patients with bronchial asthma in daily clinical practice. Adv Ther. 2017;34:2648–60.
pubmed: 29119403
pmcid: 5709454
Direkwatanachai C, Teeratakulpisarn J, Suntornlohanakul S, et al. Comparison of salbutamol efficacy in children–via the metered-dose inhaler (MDI) with Volumatic spacer and via the dry powder inhaler, Easyhaler, with the nebulizer–in mild to moderate asthma exacerbation: a multicenter, randomized study. Asian Pac J Allergy Immunol. 2011;29:25–33.
pubmed: 21560485
Wittbrodt ET, Millette LA, Evans KA, Bonafede M, Tkacz J, Ferguson GT. Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β2-agonist via dry-powder inhalers and pressurized metered-dose inhalers. Int J Chron Obstruct Pulmon Dis. 2018;14:101–14.
pubmed: 30613140
pmcid: 6307496
Malmberg LP, Pelkonen AS, Vartiainen V, Vahteristo M, Lähelmä S, Jõgi R. Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler (R) dry powder inhaler: a pooled analysis of two randomized controlled trials. J Thor Dis. 2021;13:621–31.
Mannan H, Foo SW, Cochrane B. Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices. BMC Res Notes. 2019;12:94.
pubmed: 30786914
pmcid: 6383223
Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557–82.
pubmed: 28128970
Chrystyn H. Closer to an ‘ideal inhaler’ with the Easyhaler: an innovative dry powder inhaler. Clin Drug Investig. 2006;26:175–83.
pubmed: 17163249
Ahonen A, Leinonen M, Ranki-Pesonen M. Patient satisfaction with Easyhaler
Ahn JH, Chung JH, Shin KC, et al. The effects of repeated inhaler device handling education in COPD patients: a prospective cohort study. Sci Rep. 2020;10:19676.
pubmed: 33184428
pmcid: 7665176
Small M, Anderson P, Vickers A, Kay S, Fermer S. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther. 2011;28:202–12.
pubmed: 21331556
Alvarez-Gutiérrez FJ, Gómez-Bastero Fernández A, Medina Gallardo JF, Campo Sien C, Rytilä P, Delgado RJ. Preference for Easyhaler
pubmed: 33628015
pmcid: 7897861
Valero A, Ribó P, Maíz L, et al. Asthma patient satisfaction with different dry powder inhalers. Expert Rev Respir Med. 2019;13:133–8.
pubmed: 30625015
Ribó P, Molina J, Calle M, et al. Prevalence of modifiable factors limiting treatment efficacy of poorly controlled asthma patients: EFIMERA observational study. NPJ Prim Care Respir Med. 2020;30:33.
pubmed: 32737324
pmcid: 7395116
Levy ML, Dekhuijzen PN, Barnes PJ, et al. Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT). NPJ Prim Care Respir Med. 2016;26:16017.
pubmed: 27098045
pmcid: 4839029
Haughney J, Lee AJ, McKnight E, Pertsovskaya I, O’Driscoll M, Usmani OS. Peak inspiratory flow measured at different inhaler resistances in patients with asthma. J Allergy Clin Immunol Pract. 2021;9:890–6.
pubmed: 33011302
Bloom CI, Douglas I, Olney J, D’Ancona G, Smeeth L, Quint JK. Cost saving of switching to equivalent inhalers and its effect on health outcomes. Thorax. 2019;74:1078–86.
pubmed: 31383774
Syk J, Vinge I, Sörberg M, Vahteristo M, Rytilä P. A multicenter, observational, prospective study of the effectiveness of switching from budesonide/formoterol Turbuhaler
pubmed: 30941722
pmcid: 6824392